×
ADVERTISEMENT

SEPTEMBER 30, 2020

Amid Chronic Pain Prescribing Surge, FDA Changes Benzodiazepine Labeling to Include Abuse, Addiction Warnings

With benzodiazepine prescribing increasing for approved indications and off-label uses, the FDA is taking action to make the use of the drug class safer for patients. The agency announced in a Drug Safety Communication that it is requiring an update to the boxed warning for benzodiazepines to now include the risks for abuse, misuse, addiction, physical dependence and withdrawal reactions.